A new drug approved for treatment of 'off phenomenon' in Parkinsonism:
Safinamide: Orally active Selective, reversible monoamine oxidase-B inhibitor with both dopaminergic and non-dopaminergic (glutamatergic) propeies.
Safinamide
Evenamide
Lacosamide
Ziconotide
Parkinsonism and other movement disorders